Analyst Price Targets — AMLX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 19, 2026 12:16 pm | — | Mizuho Securities | $19.00 | $14.10 | TheFly | Amylyx price target raised to $19 from $18 at Mizuho |
| February 10, 2026 11:10 am | Andrew Fein | H.C. Wainwright | $28.00 | $14.22 | TheFly | Amylyx price target raised to $28 from $20 at H.C. Wainwright |
| October 29, 2025 12:46 pm | — | Mizuho Securities | $16.00 | $13.94 | TheFly | Amylyx price target raised to $16 from $12 at Mizuho |
| October 16, 2025 11:13 am | Joel Beatty | Robert W. Baird | $19.00 | $15.79 | TheFly | Amylyx price target raised to $19 from $10 at Baird |
| September 15, 2025 10:38 am | Seamus Fernandez | Guggenheim | $25.00 | $11.85 | TheFly | Amylyx price target raised to $25 from $17 at Guggenheim |
| June 24, 2025 10:13 am | Seamus Fernandez | Guggenheim | $17.00 | $6.41 | TheFly | Amylyx initiated with a Buy at Guggenheim |
| May 6, 2025 9:00 pm | Marc Goodman | Leerink Partners | $10.00 | $4.65 | TheFly | Leerink upgrades Amylyx on avexitide growth opportunity |
| November 18, 2024 8:31 am | Joel Beatty | Robert W. Baird | $11.00 | $4.76 | StreetInsider | Baird Upgrades Amylyx Pharmaceuticals inc. (AMLX) to Outperform |
| October 23, 2024 6:03 am | Geoff Meacham | Bank of America Securities | $10.00 | $4.53 | StreetInsider | BofA Securities Upgrades Amylyx Pharmaceuticals inc. (AMLX) to Buy |
| October 18, 2024 6:44 am | Andrew Fein | H.C. Wainwright | $8.00 | $3.92 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Amylyx Pharmaceuticals inc. (AMLX) |
Latest News for AMLX
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences.
Theravance Biopharma (NASDAQ: TBPH - Get Free Report) and Amylyx Pharmaceuticals (NASDAQ: AMLX - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, profitability, analyst recommendations and institutional ownership. Profitability This table compares Theravance Biopharma and
Joshua B Cohen sold 138,167 shares for a total transaction value of ~$1.9 million on Jan. 15 and Jan. 16, 2026, at a weighted average price of $13.59 per share. This sale represented 3.93% of Cohen's direct holdings at the time, reducing his direct position from 3,517,632 to 3,379,465 shares.
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) breached their fiduciary duties to shareholders.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced the selection of AMX0318, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist, as a development candidate for post-bariatric hypoglycemia (PBH) and other rare diseases. AMX0318 was identified through a research collaboration with Gubra A/S (“Gubra”), a company specializing in…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for AMLX.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.